TissueGene Inc. is gearing to launch an initial public offering in South Korea to finance a Phase III US clinical trial of Invossa, its first-in-class cell and gene therapy drug. Invossa was approved by South Korean authorities in July making it the country's first gene therapy and the world’s first allogeneic cell mediated gene therapy for degenerative osteoarthritis.
Spotlight On TissueGene’s Upcoming Korea IPO
Regenerative drug company TissueGene’s proposed IPO in South Korea is drawing keen interest, coming close on the heels of the recent approval of its novel osteoarthritis drug in the country. Success of the IPO will be crucial for the company to proceed with a Phase III US study of the drug.
